Your Advisors
Ernie Tremblay
Ernie'S LATEST HEADLINES
-
These Promising Cancer Therapies Are a Biotech "Triple Play"
On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.
Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.
And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.
It's clear that investors can do very well with the right cancer drug.
But there, of course, is the rub: Finding the right cancer drug is not so easy.
I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize... - "21st Century Cures" Could Revolutionize Biotech
- How to Profit from America's $20 Billion Waistline War
- How to Find the Best Biotech Shares - Every Time
- These Pharma Companies Stand Between Us and the "Bacterial Apocalypse"
- One Stock That Will Profit from a New, Breakthrough Medical Direction
- The Keryx (Nasdaq: KERX) Media Blunder Will Add to Our 700% Gain
- The Clear Map to This "Hidden" Investment Treasure
- A Clear Way to Profit from a Graying Population
- The BioScience Profit Outlook for the Rest of 2014